X0508 4 2026-02-06 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001568249 Rhodes Jennifer J C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 false true false false EVP, CHIEF LEGAL OFFICER, SEC 0 Common Stock 2026-02-06 4 M 0 12944 0 A 14559 D Common Stock 2026-02-09 4 S 0 6950 23.38 D 7609 D Restricted Stock Units 2026-02-06 4 M 0 12944 0 D Common Stock 12944 12945 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Includes 595 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 50% of the restricted stock units vested on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028. /s/ Jennifer J. Rhodes 2026-02-10